These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 34339869)
21. Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer. Tang H; Chen J; Wang L; Li Q; Yang Y; Lv Z; Bao H; Li Y; Luan X; Li Y; Ren Z; Zhou X; Cong D; Liu Z; Jia J; Chen H; Zhao W; Meng Q; Sun F; Pei J Int J Pharm; 2020 Jan; 573():118806. PubMed ID: 31678519 [TBL] [Abstract][Full Text] [Related]
22. Sialic acid-modified doxorubicin liposomes target tumor-related immune cells to relieve multiple inhibitions of CD8 Du Z; Sui D; Xin D; Tang X; Li M; Liu X; Deng Y; Song Y J Liposome Res; 2024 Sep; 34(3):464-474. PubMed ID: 38196168 [TBL] [Abstract][Full Text] [Related]
23. Efficacy of epi-1 modified epirubicin and curcumin encapsulated liposomes targeting-EpCAM in the inhibition of epithelial ovarian cancer cells. Wang YJ; Tang L; Lu XH; Liu JT; Wang YY; Geng HX; Li XT; An Q J Liposome Res; 2023 Jun; 33(2):197-213. PubMed ID: 36440599 [TBL] [Abstract][Full Text] [Related]
24. The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate. She Z; Zhang T; Wang X; Li X; Song Y; Cheng X; Huang Z; Deng Y Biomaterials; 2014 Jun; 35(19):5216-25. PubMed ID: 24703714 [TBL] [Abstract][Full Text] [Related]
25. Lipid nanoparticle-based co-delivery of epirubicin and BCL-2 siRNA for enhanced intracellular drug release and reversing multidrug resistance. Yu M; Han S; Kou Z; Dai J; Liu J; Wei C; Li Y; Jiang L; Sun Y Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):323-332. PubMed ID: 28393563 [TBL] [Abstract][Full Text] [Related]
26. Liposomal Doxorubicin: the Sphingomyelin/Cholesterol System Significantly Enhances the Antitumor Efficacy of Doxorubicin. Meng X; Zhang H; Chen L; Wang M; Zhang K; Liu X; Deng Y; Song Y AAPS PharmSciTech; 2023 Feb; 24(2):64. PubMed ID: 36759405 [TBL] [Abstract][Full Text] [Related]
27. Optimization design of sialic acid derivatives enhances the performance of liposomes for modulating immunosuppressive tumor microenvironments. Sui D; Liang K; Gui Y; Du Z; Xin D; Yu G; Zhai W; Liu X; Song Y; Deng Y Life Sci; 2022 Dec; 310():121081. PubMed ID: 36273630 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid-octadecylamine conjugate. Sun J; Song Y; Lu M; Lin X; Liu Y; Zhou S; Su Y; Deng Y Eur J Pharm Sci; 2016 Oct; 93():177-83. PubMed ID: 27539143 [TBL] [Abstract][Full Text] [Related]
29. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo. Lo YL; Liu Y; Tsai JC Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284 [TBL] [Abstract][Full Text] [Related]
30. Sialic Acid Conjugate-Modified Liposomal Dexamethasone Palmitate Targeting Neutrophils for Rheumatoid Arthritis Therapy: Influence of Particle Size. Wang S; Yang S; Lai X; Song Y; Hu L; Li C; Shi T; Liu X; Deng Y; Chen G AAPS PharmSciTech; 2021 Jan; 22(1):16. PubMed ID: 33389218 [TBL] [Abstract][Full Text] [Related]
31. Are third-generation active-targeting nanoformulations definitely the best? In vitro and in vivo comparisons of pixantrone-loaded liposomes modified with different sialic acid derivatives. Song Y; She Z; Huang Z; Wang S; Liu X; Zhang Q; Sun J; Di D; Deng Y Drug Deliv Transl Res; 2022 Mar; 12(3):647-661. PubMed ID: 33928513 [TBL] [Abstract][Full Text] [Related]
32. Phosphatidylserine and/or Sialic Acid Modified Liposomes Increase Uptake by Tumor-associated Macrophages and Enhance the Anti-tumor Effect. Xu Z; Li J; Yan N; Liu X; Deng Y; Song Y AAPS PharmSciTech; 2024 Jun; 25(5):125. PubMed ID: 38834759 [TBL] [Abstract][Full Text] [Related]
33. Multifunctional Targeting Liposomes of Epirubicin Plus Resveratrol Improved Therapeutic Effect on Brain Gliomas. Kong D; Hong W; Yu M; Li Y; Zheng Y; Ying X Int J Nanomedicine; 2022; 17():1087-1110. PubMed ID: 35313461 [TBL] [Abstract][Full Text] [Related]
34. Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy. Zhu S; Li X; Luo Z; Ding M; Shi S; Zhang T Drug Deliv Transl Res; 2024 Mar; 14(3):718-729. PubMed ID: 37679600 [TBL] [Abstract][Full Text] [Related]
35. Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. Yang Q; Ma Y; Zhao Y; She Z; Wang L; Li J; Wang C; Deng Y Int J Nanomedicine; 2013; 8():1257-68. PubMed ID: 23576868 [TBL] [Abstract][Full Text] [Related]
36. Epirubicin-encapsulated long-circulating thermosensitive liposome improves pharmacokinetics and antitumor therapeutic efficacy in animals. Wu Y; Yang Y; Zhang FC; Wu C; Lü WL; Mei XG J Liposome Res; 2011 Sep; 21(3):221-8. PubMed ID: 20929434 [TBL] [Abstract][Full Text] [Related]
37. Epirubicin loaded with propylene glycol liposomes significantly overcomes multidrug resistance in breast cancer. Zhao YZ; Dai DD; Lu CT; Chen LJ; Lin M; Shen XT; Li XK; Zhang M; Jiang X; Jin RR; Li X; Lv HF; Cai L; Huang PT Cancer Lett; 2013 Mar; 330(1):74-83. PubMed ID: 23186833 [TBL] [Abstract][Full Text] [Related]
38. Sialic Acid Conjugate-Modified Cationic Liposomal Paclitaxel for Targeted Therapy of Lung Metastasis in Breast Cancer: What a Difference the Cation Content Makes. Sun W; Han C; Ge R; Jiang X; Wang Y; Han Y; Wang N; Song Y; Yang M; Chen G; Deng Y Mol Pharm; 2024 Apr; 21(4):1625-1638. PubMed ID: 38403951 [TBL] [Abstract][Full Text] [Related]
39. Sialic-Acid-Anchored Micelles: A Hierarchical Targeting Device for Enhanced Tumor Tissue Accumulation and Cellular Internalization. Zhu ML; Xu XL; Wang XJ; Zhang NN; Lu KJ; Qi J; Jin FY; Liu D; Du YZ Mol Pharm; 2018 Sep; 15(9):4235-4246. PubMed ID: 30110551 [TBL] [Abstract][Full Text] [Related]
40. Enhancement of in vitro antitumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation. Khaleseh F; Hemmati Azandaryani A; Fathian Kolahkaj F; Khazaei M; Derakhshandeh K IET Nanobiotechnol; 2021 May; 15(3):257-265. PubMed ID: 34694666 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]